OR WAIT null SECS
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Obstructive Sleep Apnea (OSA).
Clinilabs has been involved in clinical research related to the development of sleep therapeutics for 20 years. Barbara Smallwood, Vice President of Business Development, states “We are proud to continue our part in the search for new treatments for sleep disorders, and we look forward to assessing the effects of an investigational new drug on patients with OSA.”
Enrollment for this study is expected to begin in April 2011. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who have been diagnosed with OSA can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting